ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, several recent findings support ABCB1 and ABCG2-mediated efflux of asciminib, a new drug in development in CML, as the mechanism of resistance in these cell lines (10, 11).